Resource Logo
NLM AIDSLINE

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.




 

Clin Infect Dis. 1994 Oct;19(4):684-6. Unique Identifier : AIDSLINE

Eight cases of severe mucosal candidiasis in patients with AIDS who were taking fluconazole at a dosage of 400-800 mg/d are described. Candida albicans alone or in conjunction with Torulopsis glabrata or Candida stellatoidea was isolated from each patient. In vitro susceptibility testing demonstrated resistance to fluconazole in all eight cases. All tested isolates were susceptible to amphotericin B, and six of eight isolates tested were susceptible to itraconazole. All individuals were severely immunocompromised (CD4 lymphocyte counts: mean, 15/mm3; range, 6-39/mm3) and had been receiving prophylaxis with fluconazole for a mean of only 3 months (range, 1-7 months). The occurrence of candidal mucositis in patients receiving high doses of fluconazole is a matter of concern that requires further study in regard to the causes, prevention, and treatment of the disease.

Adult AIDS-Related Opportunistic Infections/*DRUG THERAPY/IMMUNOLOGY Candida/*DRUG EFFECTS Candidiasis, Oral/*DRUG THERAPY/IMMUNOLOGY Candidiasis, Vulvovaginal/*DRUG THERAPY/IMMUNOLOGY CD4 Lymphocyte Count Drug Resistance, Microbial Female Fluconazole/*PHARMACOLOGY Human Immunocompromised Host Male JOURNAL ARTICLE



 




Information in this article was accurate in April 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.